Strain Name:

FVB/N-Tg(tetO-MYC)36aBop/J

Stock Number:

019376

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
These TRE-MYC (TetO-c-Myc or Teto-MYC) hemizygous transgenic mice carry the human myelocytomatosis oncogene, MYC, regulated by a tetracycline operator (tetO). These mice may be useful for studying tumor development and regression.

Description

Strain Information

Type Coisogenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
GenerationN10+pN1 (24-MAY-13)
Generation Definitions
 
Donating Investigator J Michael Bishop,   UCSF School of Medicine

Description
Expression of MYC in these transgenic mice is regulated by a tetracycline operator (tetO). MYC is a transcription factor involved in cellular proliferation and differentiation, and is often upregulated in tumors, leukemias and lymphomas. Hemizygous mice are viable and fertile, homozygotes do not survive. When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of MYC protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring.

When bred to B6.Cg-Tg(Cebpb-tTA)5Bjd/J mice (as Stock No. 003563) expressing tTA in liver, withdrawal of dox from double transgenic mice develop invasive metastatic liver tumors, and all mice die within 2 weeks onset. When doxycycline treatment is re-administered, rapid and sustained tumor regression is evident.

When bred to B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J (see Stock No. 007176) expressing rtTA in renal tubular epithelial cells, induction of doxycycline causes polycystic kidneys, kidney failure and renal adenomas.

Development
A transgenic vector was generated encoding the human myelocytomatosis viral oncogene cDNA (MYC) under control of a tetO promoter. The construct was microinjected into FVB/NJ fertilized oocytes, and mice from founder line 36a were bred to FVB/NJ mice for at least 10 generations to establish a colony. Upon arrival at The Jackson Laboratory Repository, mice were bred to FVB/NJ mice (as Stock No. 001800) for at least one generation.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ (approximate)
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of MYC
002712   FVB/N-Tg(PF4MER)6Kra/J
View Strains carrying other alleles of MYC     (1 strain)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016178   B6(Cg)-Tg(tetO-Cry2)3Jt/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
023910   B6.Cg-Col1a1tm1(tetO-Lin28a)Gqda/J
023911   B6.Cg-Col1a1tm2(tetO-LIN28B)Gqda/J
023912   B6.Cg-Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
023642   B6;C3-Tg(tetO-AIMP2)634Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
024742   B6;DBA-Tg(tetO-GCaMP6s)2Niell/J
024088   B6;FVB-Tg(tetO-AML1/ETO)8Dzh/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
016581   C57BL/6J-Tg(tetO-Btrc*)1Jt/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
024898   C57BL/6J-Tg(tetO-EGFP/Rpl10a)5aReij/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
025672   FVB/N-Tg(tetO-Fgfr2b/Igh)1.3Jaw/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
018999   STOCK Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
025671   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(tetO-Fgf10)1Jaw/SpdlJ
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
024509   STOCK Tg(tetO-Gata6)1Abl/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (136 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Colorectal Cancer; CRC
Hepatocellular Carcinoma
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Burkitt Lymphoma; BL   (MYC)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-MYC)36aBop/0

        involves: C57BL/6 * DBA * FVB/N
  • renal/urinary system phenotype
  • kidney cysts
    • following induction with doxycycline, mice develop glomerular cysts   (MGI Ref ID J:140925)
    • polycystic kidney
      • following induction with doxycycline, mice develop multiple renal cysts in all renal tubular compartments   (MGI Ref ID J:140925)
  • kidney failure
    • 3 to 4 months following induction with doxycycline   (MGI Ref ID J:140925)
  • tumorigenesis
  • increased adenoma incidence
    • following induction with doxycycline, mice develop renal adenomas   (MGI Ref ID J:140925)
  • increased renal carcinoma incidence
    • following induction with doxycycline   (MGI Ref ID J:140925)

Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0

        involves: FVB/N * NMRI
  • mortality/aging
  • premature death
    • following withdrawal of doxycycline, all mice succumb to liver tumors within 2 weeks   (MGI Ref ID J:93899)
    • median survival of mutants is 31 weeks following doxycycline withdrawal to induce MYC expression   (MGI Ref ID J:172430)
    • median survival of mutants with tumors is 27 weeks following doxycycline withdrawal to induce MYC expression   (MGI Ref ID J:172430)
  • tumorigenesis
  • decreased tumor growth/size
    • doxycycline-treated mice infected with an adeno-associated virus-expressing Mir122 exhibit suppression of tumorigenesis tumor cell proliferation compared with control mice   (MGI Ref ID J:190067)
  • increased liver tumor incidence   (MGI Ref ID J:172430)
    • following withdrawal of doxycycline, mice develop tumors with a latency of 12 weeks and all mice succumb to liver tumors within 2 weeks   (MGI Ref ID J:93899)
    • liver tumors that develop in mice after doxycycline withdrawal are invasive and metastasis into the thoracic cavity and lung parenchyma   (MGI Ref ID J:93899)
    • however, re-establishment of doxycycline-treatment produces rapid and sustained tumor regression   (MGI Ref ID J:93899)
    • repeated withdrawal and treatment with doxycyclineinduces and represses, respectively, tumor formation   (MGI Ref ID J:93899)
    • increased hepatoblastoma incidence
      • liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas   (MGI Ref ID J:93899)
    • increased hepatocellular carcinoma incidence
      • liver tumors that develop in mice after doxycycline withdrawal resemble hepatocellular carcinomas and/or hepatoblastomas   (MGI Ref ID J:93899)
      • tumors that form in mice after doxycycline withdrawal are composed of hepatocellular neoplasms characterized by sheets of cells with occasional mitotic figure, slightly pleomorphic nuclei, and prominent nucleoli   (MGI Ref ID J:172430)
      • tumors show a range of differentiation between well- and moderately-differentiated hepatocellular carcinoma   (MGI Ref ID J:172430)
      • in doxycycline-treated mice   (MGI Ref ID J:190067)
      • however, treatment with adeno-associated virus-expressing Mir122 suppresses tumorigenesis   (MGI Ref ID J:190067)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Genes Regulating Growth and Proliferation
Increased Tumor Incidence
Oncogenes
Other
      tumor metastasis

Research Tools
Cancer Research
      Tetop Tet System
Genetics Research
      Mutagenesis and Transgenesis: Tetop Tet System
Tet Expression Systems
      tTA/rtTA Responsive Strains

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-MYC)36aBop
Allele Name transgene insertion 36a, J Michael Bishop
Allele Type Transgenic (Inducible, Inserted expressed sequence)
Common Name(s) TRE-MYC; TetO-c-Myc; Teto-MYC; Tg(tetO-MYC)36Bop;
Mutation Made By J Michael Bishop,   UCSF School of Medicine
Strain of OriginFVB/N
Expressed Gene MYC, v-myc avian myelocytomatosis viral oncogene homolog, human
Promoter tetO, tet operator,
Molecular Note This transgene contains a human v-myc avian myelocytomatosis viral oncogene homolog cDNA and regulatory elements from the bacterial tetracycline-resistance operon. There are two founder #36 lines. Transgene insertions are on an autosomal chromosome inthis line. [MGI Ref ID J:59444]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(tetO-MYC)36aBop, High Resolution Melting
Tg(tetO-MYC)36aBop, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Felsher DW; Bishop JM. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4(2):199-207. [PubMed: 10488335]  [MGI Ref ID J:59444]

Additional References

Tg(tetO-MYC)36aBop related

Beer S; Komatsubara K; Bellovin DI; Kurobe M; Sylvester K; Felsher DW. 2008. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS ONE 3(6):e2493. [PubMed: 18560566]  [MGI Ref ID J:139884]

Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW. 2004. Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol 2(11):E332. [PubMed: 15455033]  [MGI Ref ID J:93372]

Cairo S; Armengol C; De Reynies A; Wei Y; Thomas E; Renard CA; Goga A; Balakrishnan A; Semeraro M; Gresh L; Pontoglio M; Strick-Marchand H; Levillayer F; Nouet Y; Rickman D; Gauthier F; Branchereau S; Brugieres L; Laithier V; Bouvier R; Boman F; Basso G;Michiels JF; Hofman P; Arbez-Gindre F; Jouan H; Rousselet-Chapeau MC; Berrebi D; Marcellin L; Plenat F; Zachar D; Joubert M; Selves J; Pasquier D; Bioulac-Sage P; Grotzer M; Childs M; Fabre M; Buendia MA. 2008. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14(6):471-84. [PubMed: 19061838]  [MGI Ref ID J:142029]

Cao Z; Fan-Minogue H; Bellovin DI; Yevtodiyenko A; Arzeno J; Yang Q; Gambhir SS; Felsher DW. 2011. MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase. Cancer Res 71(6):2286-97. [PubMed: 21262914]  [MGI Ref ID J:170758]

Chow EK; Zhang XQ; Chen M; Lam R; Robinson E; Huang H; Schaffer D; Osawa E; Goga A; Ho D. 2011. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 3(73):73ra21. [PubMed: 21389265]  [MGI Ref ID J:170992]

Eberlin LS; Gabay M; Fan AC; Gouw AM; Tibshirani RJ; Felsher DW; Zare RN. 2014. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc Natl Acad Sci U S A 111(29):10450-5. [PubMed: 24994904]  [MGI Ref ID J:212266]

Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegue E; Tang F; Folkman J; Felsher DW. 2006. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 103(44):16266-71. [PubMed: 17056717]  [MGI Ref ID J:115637]

Goga A; Yang D; Tward AD; Morgan DO; Bishop JM. 2007. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13(7):820-7. [PubMed: 17589519]  [MGI Ref ID J:125802]

Hsu SH; Wang B; Kota J; Yu J; Costinean S; Kutay H; Yu L; Bai S; La Perle K; Chivukula RR; Mao H; Wei M; Clark KR; Mendell JR; Caligiuri MA; Jacob ST; Mendell JT; Ghoshal K. 2012. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122(8):2871-83. [PubMed: 22820288]  [MGI Ref ID J:190067]

Hu S; Balakrishnan A; Bok RA; Anderton B; Larson PE; Nelson SJ; Kurhanewicz J; Vigneron DB; Goga A. 2011. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 14(1):131-42. [PubMed: 21723511]  [MGI Ref ID J:176076]

Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297(5578):102-4. [PubMed: 12098700]  [MGI Ref ID J:77751]

Kampa KM; Acoba JD; Chen D; Gay J; Lee H; Beemer K; Padiernos E; Boonmark N; Zhu Z; Fan AC; Bailey AS; Fleming WH; Corless C; Felsher DW; Naumovski L; Lopez CD. 2009. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A 106(11):4390-5. [PubMed: 19251665]  [MGI Ref ID J:146764]

Kota J; Chivukula RR; O'Donnell KA; Wentzel EA; Montgomery CL; Hwang HW; Chang TC; Vivekanandan P; Torbenson M; Clark KR; Mendell JR; Mendell JT. 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-17. [PubMed: 19524505]  [MGI Ref ID J:151413]

Lee HG; Casadesus G; Nunomura A; Zhu X; Castellani RJ; Richardson SL; Perry G; Felsher DW; Petersen RB; Smith MA. 2009. The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol 174(3):891-7. [PubMed: 19164506]  [MGI Ref ID J:146151]

Lee HG; Chen Q; Wolfram JA; Richardson SL; Liner A; Siedlak SL; Zhu X; Ziats NP; Fujioka H; Felsher DW; Castellani RJ; Valencik ML; McDonald JA; Hoit BD; Lesnefsky EJ; Smith MA. 2009. Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One 4(9):e7172. [PubMed: 19779629]  [MGI Ref ID J:153600]

Morawski M; Pavlica S; Seeger G; Grosche J; Kouznetsova E; Schliebs R; Bruckner G; Arendt T. 2010. Perineuronal nets are largely unaffected in Alzheimer model Tg2576 mice. Neurobiol Aging 31(7):1254-6. [PubMed: 18829133]  [MGI Ref ID J:161988]

Nielsen CH; Kimura RH; Withofs N; Tran PT; Miao Z; Cochran JR; Cheng Z; Felsher D; Kjaer A; Willmann JK; Gambhir SS. 2010. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res 70(22):9022-30. [PubMed: 21062977]  [MGI Ref ID J:166856]

O'Donnell KA; Keng VW; York B; Reineke EL; Seo D; Fan D; Silverstein KA; Schrum CT; Xie WR; Mularoni L; Wheelan SJ; Torbenson MS; O'Malley BW; Largaespada DA; Boeke JD. 2012. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A 109(21):E1377-86. [PubMed: 22556267]  [MGI Ref ID J:184782]

Opavsky R; Tsai SY; Guimond M; Arora A; Opavska J; Becknell B; Kaufmann M; Walton NA; Stephens JA; Fernandez SA; Muthusamy N; Felsher DW; Porcu P; Caligiuri MA; Leone G. 2007. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A 104(39):15400-5. [PubMed: 17881568]  [MGI Ref ID J:125304]

Opavsky R; Wang SH; Trikha P; Raval A; Huang Y; Wu YZ; Rodriguez B; Keller B; Liyanarachchi S; Wei G; Davuluri RV; Weinstein M; Felsher D; Ostrowski M; Leone G; Plass C. 2007. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet 3(9):1757-69. [PubMed: 17907813]  [MGI Ref ID J:130029]

Peters SL; Hlady RA; Opavska J; Klinkebiel D; Novakova S; Smith LM; Lewis RE; Karpf AR; Simpson MA; Wu L; Opavsky R. 2013. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol Cell Biol 33(21):4321-33. [PubMed: 24001767]  [MGI Ref ID J:205419]

Podsypanina K; Politi K; Beverly LJ; Varmus HE. 2008. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A 105(13):5242-7. [PubMed: 18356293]  [MGI Ref ID J:133578]

Refaeli Y; Field KA; Turner BC; Trumpp A; Bishop JM. 2005. The protooncogene MYC can break B cell tolerance. Proc Natl Acad Sci U S A 102(11):4097-102. [PubMed: 15753301]  [MGI Ref ID J:97189]

Refaeli Y; Young RM; Turner BC; Duda J; Field KA; Bishop JM. 2008. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6(6):e152. [PubMed: 18578569]  [MGI Ref ID J:139351]

Saddic LA; Wirt S; Vogel H; Felsher DW; Sage J. 2011. Functional Interactions between Retinoblastoma and c-MYC in a Mouse Model of Hepatocellular Carcinoma. PLoS One 6(5):e19758. [PubMed: 21573126]  [MGI Ref ID J:172430]

Shachaf CM; Gentles AJ; Elchuri S; Sahoo D; Soen Y; Sharpe O; Perez OD; Chang M; Mitchel D; Robinson WH; Dill D; Nolan GP; Plevritis SK; Felsher DW. 2008. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 68(13):5132-42. [PubMed: 18593912]  [MGI Ref ID J:138881]

Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431(7012):1112-7. [PubMed: 15475948]  [MGI Ref ID J:93899]

Tao GZ; Lehwald N; Jang KY; Baek J; Xu B; Omary MB; Sylvester KG. 2013. Wnt/beta-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J Biol Chem 288(24):17214-24. [PubMed: 23620592]  [MGI Ref ID J:199603]

Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992]  [MGI Ref ID J:84503]

Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW. 2011. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 3(103):103ra99. [PubMed: 21974937]  [MGI Ref ID J:178317]

Tran TP; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW. 2008. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS ONE 3(5):e2125. [PubMed: 18461184]  [MGI Ref ID J:136212]

Traykova-Brauch M; Schonig K; Greiner O; Miloud T; Jauch A; Bode M; Felsher DW; Glick AB; Kwiatkowski DJ; Bujard H; Horst J; von Knebel Doeberitz M; Niggli FK; Kriz W; Grone HJ; Koesters R. 2008. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med 14(9):979-84. [PubMed: 18724376]  [MGI Ref ID J:140925]

Woods SL; Bishop JM. 2011. A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter. Transgenic Res 20(2):421-8. [PubMed: 20577802]  [MGI Ref ID J:170027]

Young RM; Polsky A; Refaeli Y. 2009. TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas. Blood 114(24):5016-23. [PubMed: 19755676]  [MGI Ref ID J:155497]

van Riggelen J; Muller J; Otto T; Beuger V; Yetil A; Choi PS; Kosan C; Moroy T; Felsher DW; Eilers M. 2010. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 24(12):1281-94. [PubMed: 20551174]  [MGI Ref ID J:161202]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, hemizygous mice may be bred to wildtype (non-carrier) mice from the colony or to FVB/NJ inbred mice (as Stock No. 001800). Homozygous mice do not survive.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHemizygous for Tg(tetO-MYC)36aBop  
Price per Pair (US dollars $)Pair Genotype
$304.00Hemizygous for Tg(tetO-MYC)36aBop x Noncarrier  
$304.00Noncarrier x Hemizygous for Tg(tetO-MYC)36aBop  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHemizygous for Tg(tetO-MYC)36aBop  
Price per Pair (US dollars $)Pair Genotype
$395.20Hemizygous for Tg(tetO-MYC)36aBop x Noncarrier  
$395.20Noncarrier x Hemizygous for Tg(tetO-MYC)36aBop  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Notice to customers in Canada.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)